{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:36:33Z","timestamp":1792683393779,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008130","name":"Pusan National University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.braindev.2025.104389","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:55:37Z","timestamp":1751536537000},"page":"104389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Relationship between cerebrospinal fluid cytokines\/chemokines and clinical impact of myelin oligodendrocyte glycoprotein antibody-associated disorders in children"],"prefix":"10.1016","volume":"47","author":[{"given":"SunMin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooyoung","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ook","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taek Jin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yeon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyu Min","family":"Yeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.braindev.2025.104389_bb0005","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1021\/jm010811t","article-title":"Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis","volume":"44","author":"Carotenuto","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.braindev.2025.104389_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.msard.2018.02.023","article-title":"New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases","volume":"22","author":"Di Pauli","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.braindev.2025.104389_bb0015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.braindev.2019.06.004","article-title":"Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy","volume":"41","author":"Hino-Fukuyo","year":"2019","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2025.104389_bb0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.braindev.2025.104389_bb0025","article-title":"Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases","volume":"5","author":"Hofer","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.braindev.2025.104389_bb0030","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2025.104389_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.866824","article-title":"Serum and cerebrospinal fluid biomarkers in Neuromyelitis Optica Spectrum disorder and myelin oligodendrocyte glycoprotein associated disease","volume":"13","author":"Dinoto","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.braindev.2025.104389_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149411","article-title":"B cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.braindev.2025.104389_bb0045","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000012","article-title":"Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.braindev.2025.104389_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010455","article-title":"Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica","volume":"5","author":"Mader","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.braindev.2025.104389_bb0055","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group. International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2025.104389_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International panel for NMO diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2025.104389_bb0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2025.104389_bb0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2025.104389_bb0075","series-title":"Guillain-Barr\u00e9 Syndrome Continuum (Minneap Minn)","first-page":"1184","volume":"26","author":"Sheikh","year":"2020"},{"key":"10.1016\/j.braindev.2025.104389_bb0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","article-title":"Paediatric MOG consortium consensus: part 4 - outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2025.104389_bb0085","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"BIOMARKER study group. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2025.104389_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","article-title":"Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis","volume":"289","author":"Horellou","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.braindev.2025.104389_bb0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.braindev.2025.104389_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","article-title":"IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer","volume":"22","author":"Neurath","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.braindev.2025.104389_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jneuroim.2008.04.025","article-title":"Lymphoid chemokines in chronic neuroinflammation","volume":"198","author":"Aloisi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.braindev.2025.104389_bb0110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4049\/jimmunol.181.1.186","article-title":"B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones","volume":"181","author":"Takagi","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.braindev.2025.104389_bb0115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2025.104389_bb0120","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2025.104389_bb0125","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2025.104389_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol"},{"key":"10.1016\/j.braindev.2025.104389_bb0135","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.braindev.2025.104389_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.braindev.2025.104389_bb0145","article-title":"Neuromyelitis Optica study group (NEMOS). Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and Neuromyelitis Optica Spectrum disorders","volume":"9","author":"Ringelstein","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.braindev.2025.104389_bb0150","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200150","article-title":"Dramatic response to anti-IL-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease","volume":"10","author":"McLendon","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.braindev.2025.104389_bb0155","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2025.104389_bb0160","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1177\/1352458518765677","article-title":"Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder","volume":"24","author":"Biotti","year":"2018","journal-title":"Mult Scler"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:31:33Z","timestamp":1765456293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760425000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0387760425000713"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104389","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between cerebrospinal fluid cytokines\/chemokines and clinical impact of myelin oligodendrocyte glycoprotein antibody-associated disorders in children","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104389"}}